The Edge Billion Ringgit Club Corporate Awards 2020 list of winners

Super big cap companies

Companies with more than RM40 billion market capitalisation

Highest growth in profit after tax over three years — Hartalega Holdings Bhd
Highest return on equity over three years — Maxis Bhd
Highest returns to shareholders over three years — Top Glove Corporation Bhd

EPF has around 5% holding, so how far can it push down or push up?

Covid live updates: U.S. adds 1 million cases in just four days, now above 15 million.

https://www.cnbc.com/2020/12/08/coronavirus-live-updates.html

Going at this rate, even before Pfizer - Moderna file for full-approval in Mar 2021, probably around 15% population already had Covid.

RM2.4bn PAT. As at 30 November 2020, the Group was in a net cash position of RM3.45 billion.

Total new capacity in FY21 would be 18bn or +20% from current 90bn.

With the pandemic, Top Glove estimates that glove demand will keep growing, by 20% per annum in 2020, 25% per annum in 2021 and 15% per annum post-pandemic.

More lucrative earning in 2021 due to increase in volume (+20%), higher ASP (coupled with cost pass through mechanism whereby both cost increases and savings to be shared out with customers to offset the increase in raw material price). Now, it is quite believable that Maybank Kim Eng estimates of RM11bn - 12bn is achievable.

What a stellar performance, RM2.4B despite EMCO in later part of Nov.

16.5 cents dividend is super-good, especially compared to Maybank 13.5 cents only, and a lot of upside potential. FY21 PAT definitely will surpass Maybank by a wide margin and claim the top spot in Bursa.

https://www.theedgemarkets.com/article/top-gloves-next-recordbreaking-quarterly-profit-expected-surge-past-rm2b

Tomorrrow is the QR. Let's see if TG will reward the shareholder with cash dividend or share-distribution dividend (from its Treasury share). Either way, it is acceptable.

------------------------------------------------------

The latest guidance from the Centers for Disease Control and Prevention states that the "Occupational Safety and Health Administration (OSHA) regulations have not typically required gloves to be worn when administering vaccines unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands.

***** In the setting of the COVID-19 pandemic, gloves should be worn when administering intranasal or oral vaccines." The CDC notes that if gloves are worn while administering a vaccine the healthcare worker should change them between each patient and observe proper hand-washing hygiene. *****

------------------------------------------------------

Not just that glove is still relevant into 2022/2023, but the ASP is expected to soar further due to urgency and acute shortage in tandem with Covid vaccine administration. Probably Maybank estimate of RM11B - RM12B PAT in FY21 is closer to reality which will raise TG to the top spot on corporate earning in FY21, far from the second spot which may be Maybank at around RM6B - RM8B.

The latest guidance from the Centers for Disease Control and Prevention states that the "Occupational Safety and Health Administration (OSHA) regulations have not typically required gloves to be worn when administering vaccines unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands. ***** In the setting of the COVID-19 pandemic, gloves should be worn when administering intranasal or oral vaccines." The CDC notes that if gloves are worn while administering a vaccine the healthcare worker should change them between each patient and observe proper hand-washing hygiene. *****

https://www.cbsnews.com/news/nitrile-glove-shortage-covid-19-vaccine-60-minutes-2020-12-06/

----------------------------------------------------------------

Nitrile glove will be short well into 2022, probably 2023 and beyond if Covid-19 vaccine efficacy wane after 1 or 2 years, worse still merely 4 months like flu-vaccine. You should hold-on to your ticket or consider to top up as it is greatly undervalue low.

https://www.cbsnews.com/news/nitrile-glove-shortage-covid-19-vaccine-60-minutes-2020-12-06/

The latest guidance from the Centers for Disease Control and Prevention states that the "Occupational Safety and Health Administration (OSHA) regulations have not typically required gloves to be worn when administering vaccines unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands. ***** In the setting of the COVID-19 pandemic, gloves should be worn when administering intranasal or oral vaccines." The CDC notes that if gloves are worn while administering a vaccine the healthcare worker should change them between each patient and observe proper hand-washing hygiene. *****

----------------------------------------------------------------

Nitrile glove will be short well into 2022, probably 2023 and beyond if Covid-19 vaccine efficacy wane after 1 or 2 years, worse still merely 4 months like flu-vaccine. You should hold-on to your ticket or consider to top up as it is greatly undervalue low.

<Beginner_Newbie> Defintely Glove will shoot up because it is undervalue. Glove are still in great demand despite Vaccine. MIDF expect the world would be still short of 30 billion gloves into 2022 (not even 2021). A value investor like Warren Buffet will buy good fundamental stock which is greatly undervalue due to temporary weak sentiment or insensible sell-down.

This would be a brutal winter and after all the euphoria associated with Biden victory, vaccine "perceived" success, Thankgiving holiday, Christmas holiday started to subside, people will come back to reality.

Probably even we Malaysians just have to live with this persisting 1,000 Covid cases on daily basis and observe the SOP. At the end of the day, no science can save us from ourselves.

<shareshareonly> Comfort latest QR was on Nov 30 2020,

https://www.klsescreener.com/v2/stocks/view/2127/comfort-gloves-berhad.

At current price, the P/E would reduce down to single digit on next QR thus undervalue. Good time to accumulate.

When you run, please make sure that you don't shout run again and again, day after day. Please make sure that you run away from this forum for good.

This is investment, not speculation nor having the foresight, foretell ability. Probably the CMCO/RMCO depression got into someone and start hallucinating.

If you can't control yourself (or your emotion), you control nothing.

As MIDF pointed out below (today, Dec 03 2020), glove is still significantly short even in 2022 (by more than 30 billion), and that demand will be continued to be supported by mass-testing and administration of Covid-19 vaccine, when they are available. Vaccination will take a long long time, and even Malaysia may only vaccinate 20% of its vaccination. Vaccine lead time would be long, just like the glove up to 600 days (if nothing goes wrong along the way).

----------------------------------------------------------------------------------------------

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-filli...

MIDF Amanah Investment Bank Bhd analysts wrote in a note today that the rubber glove “shortage is likely to persist into 2021 as supply is unlikely to keep up with demand yet” as the world contends with the Covid-19 pandemic.

The analysts said 2020 had been an exceptional year for glove companies due to a surprise surge in demand for rubber gloves following the Covid-19 outbreak.

According to them, the glove industry as a whole is expected to increase production, but that may be constrained by raw material, production line contractor and foreign labour shortages.

"As such, we expect demand to outstrip supply by 30 billion pieces in 2020, 45.8 billion pieces in 2021 and 33.4 billion pieces in 2022.

"In 2021, demand will continue to be supported by mass testing and administration of Covid-19 vaccines when they are available,” the analysts said.

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-filli...

*** If you see people sanitize the glove instead of changing to a new one (or not wearing a mask), don't assume that is the SOP. It is a violation of SOP, thus you should report the incident if you really care ***

These are very conservative estimates :

Number of Shares : 8.196 billion

Q1 2021 RM2B PAT 0.46 EPS, thus RM9.20, in case of P/E = 20
Q2 2021 RM2B PAT 0.69 EPS, thus RM13.80, in case of P/E = 20
Q3 2021 RM2B PAT 0.89 EPS, thus RM17.80, in case of P/E = 20
Q4 2021 RM2B PAT 0.98 EPS, thus RM19.60, in case of P/E = 20

NOTE : Q1 refers to Aug 31 to Nov 30 2020 (and QR is expected on Dec 9 2020) thus Q4 would translate to Aug 31 2021.

Some IBs are estimating Topglov will see more than RM10B PAT in FY21 even up to RM12B (as per Maybank estimation) while we are only assuming RM8B. Historically, TopGlov is traded at P/E = 30 and above but we are conservatively assuming P/E = 20.

***** A good value-investor like Warren Buffet will take its position when a good fundamental stock is undervalue (insensibly sell-off by temporary weak sentiment or negative emotion).

As MIDF pointed (today, Dec 03 2020), glove is still significantly short even in 2022 (by more than 30 billion), and that demand will be continued to be supported by mass-testing and administration of Covid-19 vaccine, when they are available. Vaccination will take a long long time, and even Malaysia may only vaccinate 20% of its population in 2021. Vaccine lead time would be long, just like the glove up to 600 days (if nothing goes wrong along the way).

----------------------------------------------------------------------------------------------

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-filli...

U.S. tops ‘unfathomable’ milestone of 100,000 Covid hospitalizations: ‘We’re all on edge’

PUBLISHED WED, DEC 2 20207:15 PM ESTUPDATED WED, DEC 2 20207:25 PM EST

“We’re running out of beds, and we’re also going to run out of staff,” said Dr. Megan Ranney, an emergency physician and director of the Brown-Lifespan Center for Digital Health.

--------------------------------------------------------------

This is gonna be a brutal winter...................... The vaccine is still in trial, not approved, only may-be granted emergency temporary registration for limited use. In case of emergency use, you'll need to sign no-liability/indemnity letter thus government bear no responsibility and if you develop any Covid vaccine related minor/major sickness now or later, insurance will not cover.

Emergency use is only for morale support, not going to slow-down the number of infections neither death. People need to realize that they need to do their part to contain the virus like China/Taiwan, not merely relying or hoping for a silver-bullet.

U.S. tops ‘unfathomable’ milestone of 100,000 Covid hospitalizations: ‘We’re all on edge’

PUBLISHED WED, DEC 2 20207:15 PM ESTUPDATED WED, DEC 2 20207:25 PM EST

“We’re running out of beds, and we’re also going to run out of staff,” said Dr. Megan Ranney, an emergency physician and director of the Brown-Lifespan Center for Digital Health.

--------------------------------------------------------------

This is gonna be a brutal winter...................... The vaccine is still in trial, not approved, only may-be granted emergency temporary registration for limited use. In case of emergency use, you'll need to sign no-liability/indemnity letter thus government bear no responsibility and if you develop any Covid vaccine related minor/major sickness now or later, insurance will not cover.

Emergency use is only for morale support, not going to slow-down the number of infections neither death. People need to realize that they need to do their part to contain the virus like China/Taiwan, not merely relying or hoping for a silver-bullet.

U.S. tops ‘unfathomable’ milestone of 100,000 Covid hospitalizations: ‘We’re all on edge’

PUBLISHED WED, DEC 2 20207:15 PM ESTUPDATED WED, DEC 2 20207:25 PM EST

“We’re running out of beds, and we’re also going to run out of staff,” said Dr. Megan Ranney, an emergency physician and director of the Brown-Lifespan Center for Digital Health.

--------------------------------------------------------------

This is gonna be a brutal winter...................... The vaccine is still in trial, not approved, only may-be granted emergency temporary registration for limited use. In case of emergency use, you'll need to sign no-liability/indemnity letter thus government bear no responsibility and if you develop any Covid vaccine related minor/major sickness now or later, insurance will not cover.

Emergency use is only for morale support, not going to slow-down the number of infections neither death. People need to realize that they need to do their part to contain the virus like China/Taiwan, not merely relying or hoping for a silver-bullet.

As MIDF pointed out below (today, Dec 03 2020), glove is still significantly short even in 2022 (by more than 30 billion), and that demand will be continued to be supported by mass-testing and administration of Covid-19 vaccine, when they are available. Vaccination will take a long long time, and even Malaysia may only vaccinate 20% of its vaccination. Vaccine lead time would be long, just like the glove up to 600 days (if nothing goes wrong along the way).

----------------------------------------------------------------------------------------------

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-filli...

MIDF Amanah Investment Bank Bhd analysts wrote in a note today that the rubber glove “shortage is likely to persist into 2021 as supply is unlikely to keep up with demand yet” as the world contends with the Covid-19 pandemic.

The analysts said 2020 had been an exceptional year for glove companies due to a surprise surge in demand for rubber gloves following the Covid-19 outbreak.

According to them, the glove industry as a whole is expected to increase production, but that may be constrained by raw material, production line contractor and foreign labour shortages.

"As such, we expect demand to outstrip supply by 30 billion pieces in 2020, 45.8 billion pieces in 2021 and 33.4 billion pieces in 2022.

"In 2021, demand will continue to be supported by mass testing and administration of Covid-19 vaccines when they are available,” the analysts said.

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-fillip-bursa-after-sp-500-ends-record-high

As MIDF pointed out below (today, Dec 03 2020), glove is still significantly short even in 2022 (by more than 30 billion), and that demand will be continued to be supported by mass-testing and administration of Covid-19 vaccine, when they are available. Vaccination will take a long long time, and even Malaysia may only vaccinate 20% of its vaccination. Vaccine lead time would be long, just like the glove up to 600 days (if nothing goes wrong along the way).

----------------------------------------------------------------------------------------------

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-filli...

MIDF Amanah Investment Bank Bhd analysts wrote in a note today that the rubber glove “shortage is likely to persist into 2021 as supply is unlikely to keep up with demand yet” as the world contends with the Covid-19 pandemic.

The analysts said 2020 had been an exceptional year for glove companies due to a surprise surge in demand for rubber gloves following the Covid-19 outbreak.

According to them, the glove industry as a whole is expected to increase production, but that may be constrained by raw material, production line contractor and foreign labour shortages.

"As such, we expect demand to outstrip supply by 30 billion pieces in 2020, 45.8 billion pieces in 2021 and 33.4 billion pieces in 2022.

"In 2021, demand will continue to be supported by mass testing and administration of Covid-19 vaccines when they are available,” the analysts said.

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-filli...

MIDF Amanah Investment Bank Bhd analysts wrote in a note today that the rubber glove “shortage is likely to persist into 2021 as supply is unlikely to keep up with demand yet” as the world contends with the Covid-19 pandemic.

The analysts said 2020 had been an exceptional year for glove companies due to a surprise surge in demand for rubber gloves following the Covid-19 outbreak.

According to them, the glove industry as a whole is expected to increase production, but that may be constrained by raw material, production line contractor and foreign labour shortages.

"As such, we expect demand to outstrip supply by 30 billion pieces in 2020, 45.8 billion pieces in 2021 and 33.4 billion pieces in 2022.

"In 2021, demand will continue to be supported by mass testing and administration of Covid-19 vaccines when they are available,” the analysts said.

https://www.theedgemarkets.com/article/top-glove-hartalega-offer-fillip-bursa-after-sp-500-ends-record-high

MIDF Amanah Investment Bank Bhd analysts wrote in a note today that the rubber glove “shortage is likely to persist into 2021 as supply is unlikely to keep up with demand yet” as the world contends with the Covid-19 pandemic.

The analysts said 2020 had been an exceptional year for glove companies due to a surprise surge in demand for rubber gloves following the Covid-19 outbreak.

According to them, the glove industry as a whole is expected to increase production, but that may be constrained by raw material, production line contractor and foreign labour shortages.

"As such, we expect demand to outstrip supply by 30 billion pieces in 2020, 45.8 billion pieces in 2021 and 33.4 billion pieces in 2022.

"In 2021, demand will continue to be supported by mass testing and administration of Covid-19 vaccines when they are available,” the analysts said.

Shareholders

Top Glove Corporation Bhd. (MYL7113OO003)

Name Equities %

Wee-Chai Lim 2,091,376,456 (25.5%)
Firstway United Corp. 554,966,328 (6.77%)
Employees Provident Fund 513,355,166 (6.27%)
Bank of Singapore Ltd. 295,233,800 (3.60%)
The Vanguard Group, Inc. 193,341,039 (2.36%)
Kumpulan Wang Persaraan 184,875,400 (2.26%)
UBS AG (Private Banking Singapore) 165,282,800 (2.02%)
MFP Capital Corp. 134,700,000 (1.64%)
AIA Bhd. 129,630,700 (1.58%)
Hooi Sin Lim 112,061,244 (1.37%)

https://www.cnbc.com/2020/12/02/drugmaker-merck-divests-its-investment...

U.S. drugmaker Merck said on Wednesday it has sold its equity investment in Moderna, after benefiting from a surge in the stock price of the vaccine developer this year.

The one who knows everything and would have beaten Boris to it, to be the first western country to approve Covid-19 trial vaccine for emergency use is sadly or gladly losing his presidency.

Now we can see how these western superpowers handle crisis...... bending rules, cutting corners, etc.

-------------------------------------------------------------

“I have confidence in Biontech, but ‘Confidence is good, control is better’. Emergency authorisation is a tool normally intended for patients who suffer from a serious and incurable disease and where there is no other means of saving life or physical integrity. This is not the case with corona,” the statement read.

Peter Liese, a European Union lawmaker and physician

https://www.cnbc.com/2020/12/02/drugmaker-merck-divests-its-investment-in-moderna.html

U.S. drugmaker Merck said on Wednesday it has sold its equity investment in Moderna, after benefiting from a surge in the stock price of the vaccine developer this year.

https://www.thestar.com.my/opinion/columnists/so-aunty-so-what/2020/12/02/mask-is-a-must-even-with-a-vaccine

More approval for emergency use is expected i.e. Pfizer (Dec 10) and Moderna (Dec 17). This is indeed a good thing but unfortunately record high Covid infections and death will be recorded throughout this brutal winter.

For now, we will see how this so-claimed high efficacy vaccines work in a bigger group, and hopefully we will get a million volunteers in no time.

Such political gesture will buy some time for these so-called leaders incl. Boris who is push to the corner with Brexit coupled with Covid.

Mercator 52wk low is 7.74 and 52 wk high is 770, almost 100X. Fuyoh!

Even if comparing the spread from Mar 18/19 to todays' price, it has gone up by more than 30X as compared to TG, merely 3X - 4X.

If we were to equate TG to Mercator, what is the potential of TG? Anywhere, that is not the right way to compare.

AMBank is not completely wrong on the TP but it was referred to FY22 not FY21, thus they incorporate their set of assumptions so no one can find fault with them at this point in time.

The only question is why FY22?, why not FY21? And how good is their prediction? They are making tens and hundreds of predictions and most often unreliable. Otherwise, the analyst is already a multi-millionaire or billionaire instead of salary-man. Unless the analyst says, "I standby by my estimation and I will not take a single cent (or pay) till end of 2022", otherwise we just take it with a pinch of salt what he/she has to say.

Macquarie also came out with their prediction/estimation till FY23. How pathetic! There are thousands and millions of these analysts saying different things everyday throughout the world, and some may get lucky and boast how their prediction was realized but the truth is, it was just a fluke and they failed 9,999 times in their prediction, and they are just as broke as they were before.

TG fundamental is intact and remain strong. Just that it is down with flu and due to recover shortly. Just like Dwayne Johnson (the Rock) taking a couple weeks break after tested positive for Covid-19 back in Sep.

It is good that emergency approval for Pfizer/Moderna will be granted soon thus they can vaccinate, hopefully several millions, during this brutal winter season where Covid-19 peaked, and esp. involving people who are at higher risk i.e. frontliners, elderly, etc, thus a bigger picture can be seen. Otherwise, it will coincide with sharp drop of infections as seen in Mar - Jun 2020 which is below 50k daily cases as oppose to 150k to 200k daily cases in late autumn - early winter.

These are very conservative estimates :

Number of Shares : 8.196 billion

Q1 2021 RM2B PAT 0.46 EPS, thus RM9.20, in case of P/E = 20
Q2 2021 RM2B PAT 0.69 EPS, thus RM13.80, in case of P/E = 20
Q3 2021 RM2B PAT 0.89 EPS, thus RM17.80, in case of P/E = 20
Q4 2021 RM2B PAT 0.98 EPS, thus RM19.60, in case of P/E = 20

NOTE : Q1 refers to Aug 31 to Nov 30 2020 (and QR is expected on Dec 9 2020) thus Q4 would translate to Aug 31 2021.

Some IBs are estimating Topglov will see more than RM10B PAT in FY21 even up to RM12B (as per Maybank estimation) while we are only assuming RM8B. Historically, TopGlov is traded at P/E = 30 and above but we are conservatively assuming P/E = 20.

***** Even AMInvest is giving an unfavorable P/E = 25 (reduced from P/E = 28) today with fair value of RM7.03 and a HOLD position, but if this were to apply when the QR is released next week, the fair value would be RM11.50, in case P/E = 25, so the review will then change to ADD in a matter of one week *****

Hold for the medium term as the upcoming quarters are "guaranteed" seeing bombarstic profit after tax (PAT).

<<< kakashi >>> Yeah. Sentiment is not good but that is already expected and probably remain throughout the month of Dec esp. when the vaccines will be approved for emergency use after Dec 10 (Pfizer) and Dec 17 (Moderna) respectively. And this is a haven for short-term trader, reaping from the daily/weekly swing. By the way, Comfort is enjoying a much lower P/E compared to the big 4. The price will shoot up before next QR or that investors may even push it up way before the next QR, otherwise if many shortcomings on vaccines were reported prematurely.

This will be a brutal winter and many more death will be resulted, unfortunately. The euphoria of Biden victory followed by vaccine news, Thanksgiving holiday, upcoming Christmas will wear off eventually.

Please note that typical glove shelf life is 3 years to 4 years depending on the storage condition. Medical establishment are running low and running out of gloves already and they will need to restock and presently they are willing to be put in the queue despite having to wait for 1 year or more. If I were in their position, I would do the same instead of getting the blame for not getting the stock in place since it will be paid by the hospital/government, insurance, patients, etc anywhere.

Also, please bear in mind that the medical establishment need to treat many many other prevailing sickness be it minor or major. Cancer and heat attack death are many times more than Covid. Even when I undergo a minor procedure which require overnight stay in the hospital, they utilize as many as 10 pairs of glove i.e. nitrile plus surgical glove. The nitrile and surgical glove then was billed at around RM6 and RM20 per pair respectively during pre-Covid era, not sure how much it is today.

<<< tonypang01 >>> For sure, Q2 FY21 will be affected by EMCO. CGS-CIMB is estimating it may be -1.3% to -1.8% of the annual profit. https://www.theedgemarkets.com/article/cgscimb-sees-negative-impact-top-glove-forecast-due-emco

Conservatively, we take an estimate of -4.0% to cover extended EMCO, blah, blah, blah to satisfy the naysayers. Again, let's assume RM8B FY21 annual profit, -4% would translate to -RM320M which is not so significant.

If PAT for Q2 2021 drop to RM1.68B PAT or 0.65 EPS, thus RM13.00 in case of P/E = 20

Furthermore, we are taking a very very conservative estimate above, though some IBs even suggested it may reach RM3B in Q2 FY21 onwards while we are only taking an estimate of RM2B, because ASP is still increasing month-on-month.

Glove are still short at least till end of FY2021. Previously Topglov claim the leadtime for nitrile is up to 600 days and if this still holds, this would translate to 1H 2022. Even if vaccine is approved for mass innoculation after 1H 2021, 70% herd immunity can only be achieved in late 2022 (at the earliest). But we are still unsure if these vaccines are really effective, long-lasting and safe. The big Phama executives are only interested to make money, and push their share price high.

Malaysia may only vaccinate 20% of its population next year, and that is only "maybe" if you trust the politicians.

<<< gemfinder >>> Real value investor are interested in profit and performance especially big funds unless the fund manager want to be screwed. They have guidelines to be followed. EPF also has guideline. They will maintain a huge percentage as medium term to long-term holdings and small percentage to trade on daily basis. At least, towards end of the year, their book has to look good.

<<< AXE666 >>> Yes, you are right. People are cursing or spewing acid and distorting the facts because they are trying to buy cheap ticket from others or that they are a gambler/speculator hoping to make instant spectacular gain with good understanding.

These are very conservative estimates :

Number of Shares : 8.196 billion

Q1 2021 RM2B PAT 0.46 EPS, thus RM9.20, in case of P/E = 20
Q2 2021 RM2B PAT 0.69 EPS, thus RM13.80, in case of P/E = 20
Q3 2021 RM2B PAT 0.89 EPS, thus RM17.80, in case of P/E = 20
Q4 2021 RM2B PAT 0.98 EPS, thus RM19.60, in case of P/E = 20

NOTE : Q1 refers to Aug 31 to Nov 31 2020 (and QR is expected on Dec 9 2020) thus Q4 would translate to Aug 31 2021.

Some IBs are estimating Topglov will see more than RM10B PAT in FY21 even up to RM12B (as per Maybank estimation) while we are only assuming RM8B. Historically, TopGlov is traded at P/E = 30 and above but we are conservatively assuming P/E = 20.

Hold for the medium term as the upcoming quarters are "guaranteed" seeing bombarstic profit after tax (PAT).

Klang is a big place not a Taman. I was raised in Klang but moved to KL after having family. Do not agree that it is a ghost town. By right shouldn't go to Klang since inter-district travel is forbidden but somehow can't resist the childhood eateries. Some places are still pack (though numbers had dwindled due to SOP) and I can't say that is happening all over Klang since it is a big place.

Please don't make up story and make people believe that Klang is a just a Kampung and there are only Top Glove, Supermax, Mah Sing, etc.

“Based on discussion and feedback from our partners worldwide, the group is of the opinion that this will become a new market requirement that will shape all future glove demand globally. The emphasis on hygiene and sanitation will also not be reduced in the event a vaccine becomes generally available,” said Comfort Gloves.

>>>> What is there to be panic?, as TopGlove shareholders. Guaranteed record breaking profit quarter after quarter at least till end of 2021. And, glove will be in great demand (or unable to meet the demand) even if vaccine is approved for mass inoculation no earlier than 1H 2021 and foreseeable immediate approval may be granted for emergency use only.

The only ones who are panicking are the IBs, fund managers because there are so many call warrants and they need to delivery full year result by year end. They are running out of time. How they wish they can deliver stellar results like TopGlove.

It's emotion, emotion, emotion ....................................

it's weird that someone claim taking a few days off to enjoy life, as though you can travel freely and tune-off completely. At most, only stay within the same district. We are now connected 24/7 regardless which part of the world you are in.

Technical Analysis is not absolute but can serve as a guide. Emotion plays a major role. With the same chart, 1,000 experts and economist will interpret differently and also applying different method.

---------------------------------------------------------------------------

Oddly enough, despite 75 years of success achieved by value investors, one group of observers largely ignores or dismisses this discipline: academics. Academics tend to create elegant theories that purport to explain the real world but in fact oversimplify it.

- Benjamin Graham (Warren Buffet's Guru)

---------------------------------------------------------------------------

So even you have a PhD as chartist, so what? How many PhDs out there are smart investor?

https://www.nst.com.my/business/2020/09/625437/top-glove-spend-rm8b-capex-next-six-years

Sep 18 2020

Top Glove executive chairman Tan Sri Dr Lim Wee Chai said the capex would be invested in several key areas including new capacity, enhancement of existing manufacturing facilities, Industry 4.0 initiatives, a gamma sterilisation plant, land bank for future expansion, IT upgrades, as well as workers' facilities.

------------------------------------------------------------------------------------

Automation is inevitable and it is just a matter of time. Harta is leading the packs with IR4.0, energy efficient system (i.e. Solar + Cogeneration system), etc. Its upcoming NGC2.0 is Banting would be state of the art, though existing NGC1.0 and more immediate NGC1.5 in Sepang is equally "canggih". Harta is run by second generation, graduated from UK and they wanting to build an international class company with contemporary working culture (sending the staff to Google to learn and emulate the business culture). Business model-wise Supermax OBM model seemed to be the highlight during this crisis.

Anyway, I'm holding all BIG 4. Which will come out at the top in coming 5 years? No one ones but they would definitely make Malaysians proud.

LWC is the TopGlove founder with only one production line and fewer than 100 staff back in 1991 to a multibillion industry with manufacturing facilities in several locations in the region, marketing offices across the globe and serving international market while the industry is growing by leaps and bounds, you will know this is a promising company with good track of record and that the founder will clinch to it till his final day in this world. Further, Top Glove is the global-leader in glove manufacturing of which we Msians could be proud of (instead of the bogus 1MDB), and aspire to be a Fortune 500 company by 2035.

Be proud! If you look at the pathetic glove manufacturing facility in US, you'll cry for them.

P/S : Having said that, I do not agree with the way how TopGlove handle the foreign workers and presumably this will improve from Dec onwards. The reason was because I used to work in US and at least they treated us equal to (or at least somewhat on par with) local Americans. That was why I prefer Harta over TopGlove though I hold shares in all BIG 4.

SHARE BUYBACK (Warren Buffet)

In Warren Buffet's mind, the only reasonable and responsible course for companies that have a growing pile of cash that cannot be reinvested at above-average rates is to return that money to the shareholders. For that two methods are available (1) initiating or raising a dividend and (2) buying back shares.

When management repurchases stock, Buffet feels that the reward is twofold. If the stock is selling below its intrinsic value, then purchasing shares makes good business sense. If a company's stock price is $50 and its intrinsic value is $100, then each time management buys its stock, it is acquiring $2 of intrinsic value for every $1 spent. Transactions of this nature can be very profitable for the remaining shareholders.

Furthermore, Buffet says, when executive actively buy the company's stock in the market, they are demonstrating that they have the best interests of their owners at heart, rather than a careless need to expand the corporate structure.

-------------------------------------------------------------------------

It is just a matter of time, the share will fly after all the market-maker and operators running out of steam to press-down the share as TopGlove are expected to earn RM12B+ in 2021, or average to about RM60M per trading day to counter the non-sensible suppression.

As a vendor, I prefer Harta over TopGlove because TopGlove left you with bones only but as an investor, TopGlove is making every calculated move to maximize profit. Datuk LCW would not do share buyback for nothing. If you are a vendor to TopGlove, you'll know what I mean. Despite huge cash pile, they are still asking vendors to offer rental-program instead of self-invest by TopGlove.

Shareholders

Top Glove Corporation Bhd. (MYL7113OO003)

Name Equities %

Wee-Chai Lim 2,091,376,456 (25.5%)
Firstway United Corp. 554,966,328 (6.77%)
Employees Provident Fund 513,355,166 (6.27%)
Bank of Singapore Ltd. 295,233,800 (3.60%)
The Vanguard Group, Inc. 193,341,039 (2.36%)
Kumpulan Wang Persaraan 184,875,400 (2.26%)
UBS AG (Private Banking Singapore) 165,282,800 (2.02%)
MFP Capital Corp. 134,700,000 (1.64%)
AIA Bhd. 129,630,700 (1.58%)
Hooi Sin Lim 112,061,244 (1.37%)

Record profit in coming quarter after quarter. Cash rich! Glove will become a new market requirement and will shape all future glove demand globally despite vaccine becomes generally available as quoted by Comfort below.

“Based on discussion and feedback from our partners worldwide, the group is of the opinion that this will become a new market requirement that will shape all future glove demand globally. The emphasis on hygiene and sanitation will also not be reduced in the event a vaccine becomes generally available,” said Comfort Gloves.

Comfort PAT about twice of that in last quarter, will all glove manufacturers seeing the same trend? And this is not the best quarter as yet.

“Based on discussion and feedback from our partners worldwide, the group is of the opinion that this will become a new market requirement that will shape all future glove demand globally. The emphasis on hygiene and sanitation will also not be reduced in the event a vaccine becomes generally available,” said Comfort Gloves.

Comfort PAT about twice of that in last quarter, will all glove manufacturers seeing the same trend?

“Based on discussion and feedback from our partners worldwide, the group is of the opinion that this will become a new market requirement that will shape all future glove demand globally. The emphasis on hygiene and sanitation will also not be reduced in the event a vaccine becomes generally available,” said Comfort Gloves.

Comfort PAT about twice of that in last quarter, will all glove manufacturers seeing the same trend? Huat arh......

“Based on discussion and feedback from our partners worldwide, the group is of the opinion that this will become a new market requirement that will shape all future glove demand globally. The emphasis on hygiene and sanitation will also not be reduced in the event a vaccine becomes generally available,” said Comfort Gloves.

SHARE BUYBACK (Warren Buffet)

In Warren Buffet's mind, the only reasonable and responsible course for companies that have a growing pile of cash that cannot be reinvested at above-average rates is to return that money to the shareholders. For that two methods are available (1) initiating or raising a dividend and (2) buying back shares.

When management repurchases stock, Buffet feels that the reward is twofold. If the stock is selling below its intrinsic value, then purchasing shares makes good business sense. If a company's stock price is $50 and its intrinsic value is $100, then each time management buys its stock, it is acquiring $2 of intrinsic value for every $1 spent. Transactions of this nature can be very profitable for the remaining shareholders.

Furthermore, Buffet says, when executive actively buy the company's stock in the market, they are demonstrating that they have the best interests of their owners at heart, rather than a careless need to expand the corporate structure.

SHARE BUYBACK (Warren Buffet)

In Warren Buffet's md, the only reasonable and responsible course for companies that have a growing pile of cash that cannot be reinvested at above-average rates is to return that money to the shareholders. For that two methods are available (1) initiating or raising a dividend and (2) buying back shares.

When management repurchases stock, Buffet feels that the reward is twofold. If the stock is selling below its intrinsic value, then purchasing shares makes good business sense. If a company's stock price is $50 and its intrinsic value is $100, then each time management buys its stock, it is acquiring $2 of intrinsic value for every $1 spent. Transactions of this nature can be very profitable for the remaining shareholders.